Dexrazoxane for the treatment of chemotherapy-related side effects

For more than half a century, the different properties of dexrazoxane have captured the attention of scientists and clinicians. Presently, dexrazoxane is licensed in many parts of the world for two different indications: prevention of cardiotoxicity from anthracycline-based chemotherapy, and prevent...

Descripción completa

Detalles Bibliográficos
Autor principal: Langer, Seppo W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4168851/
https://www.ncbi.nlm.nih.gov/pubmed/25246808
http://dx.doi.org/10.2147/CMAR.S47238
_version_ 1782335630007599104
author Langer, Seppo W
author_facet Langer, Seppo W
author_sort Langer, Seppo W
collection PubMed
description For more than half a century, the different properties of dexrazoxane have captured the attention of scientists and clinicians. Presently, dexrazoxane is licensed in many parts of the world for two different indications: prevention of cardiotoxicity from anthracycline-based chemotherapy, and prevention of tissue injuries after extravasation of anthracyclines. This article reviews the historical, preclinical, and clinical background for the use of dexrazoxane for these indications.
format Online
Article
Text
id pubmed-4168851
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-41688512014-09-22 Dexrazoxane for the treatment of chemotherapy-related side effects Langer, Seppo W Cancer Manag Res Review For more than half a century, the different properties of dexrazoxane have captured the attention of scientists and clinicians. Presently, dexrazoxane is licensed in many parts of the world for two different indications: prevention of cardiotoxicity from anthracycline-based chemotherapy, and prevention of tissue injuries after extravasation of anthracyclines. This article reviews the historical, preclinical, and clinical background for the use of dexrazoxane for these indications. Dove Medical Press 2014-09-15 /pmc/articles/PMC4168851/ /pubmed/25246808 http://dx.doi.org/10.2147/CMAR.S47238 Text en © 2014 Langer. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Langer, Seppo W
Dexrazoxane for the treatment of chemotherapy-related side effects
title Dexrazoxane for the treatment of chemotherapy-related side effects
title_full Dexrazoxane for the treatment of chemotherapy-related side effects
title_fullStr Dexrazoxane for the treatment of chemotherapy-related side effects
title_full_unstemmed Dexrazoxane for the treatment of chemotherapy-related side effects
title_short Dexrazoxane for the treatment of chemotherapy-related side effects
title_sort dexrazoxane for the treatment of chemotherapy-related side effects
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4168851/
https://www.ncbi.nlm.nih.gov/pubmed/25246808
http://dx.doi.org/10.2147/CMAR.S47238
work_keys_str_mv AT langerseppow dexrazoxaneforthetreatmentofchemotherapyrelatedsideeffects

Ejemplares similares